share_log

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

诺和诺德 | 6-K:诺和诺德-股票回购计划

SEC announcement ·  02/22 06:11
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program is part of a larger 12-month initiative to buy back shares worth up to DKK 20 billion, which started on the same date in 2023. As of February 19, 2024, the company has repurchased 394,500 B shares at an average price of DKK 830.60, totaling DKK 327,673,060. This buyback is in line with the Safe Harbour Rules of the European Union. Novo Nordisk, which has a strong heritage in diabetes care, is committed to defeating serious chronic diseases and employs approximately 63,400 people worldwide. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program is part of a larger 12-month initiative to buy back shares worth up to DKK 20 billion, which started on the same date in 2023. As of February 19, 2024, the company has repurchased 394,500 B shares at an average price of DKK 830.60, totaling DKK 327,673,060. This buyback is in line with the Safe Harbour Rules of the European Union. Novo Nordisk, which has a strong heritage in diabetes care, is committed to defeating serious chronic diseases and employs approximately 63,400 people worldwide. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.
全球领先的医疗保健公司诺和诺德A/S宣布继续其股票回购计划,该计划于2024年2月6日开始。该计划是2023年同日启动的为期12个月的更大规模计划的一部分,该计划旨在回购价值高达200亿丹麦克朗的股票。截至2024年2月19日,该公司已回购了394,500股B股,平均价格为830.60丹麦克朗,总额为327,673,060丹麦克朗。此次回购符合欧盟的《安全港规则》。诺和诺德在糖尿病护理方面有着悠久的传统,致力于战胜严重的慢性病,在全球拥有约63,400名员工。该公司的B股在哥本哈根纳斯达克上市,其ADR在纽约证券交易所上市。
全球领先的医疗保健公司诺和诺德A/S宣布继续其股票回购计划,该计划于2024年2月6日开始。该计划是2023年同日启动的为期12个月的更大规模计划的一部分,该计划旨在回购价值高达200亿丹麦克朗的股票。截至2024年2月19日,该公司已回购了394,500股B股,平均价格为830.60丹麦克朗,总额为327,673,060丹麦克朗。此次回购符合欧盟的《安全港规则》。诺和诺德在糖尿病护理方面有着悠久的传统,致力于战胜严重的慢性病,在全球拥有约63,400名员工。该公司的B股在哥本哈根纳斯达克上市,其ADR在纽约证券交易所上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息